Jasper Therapeutics, Inc. (JSPR), a key player in the biopharmaceutical industry, experienced a significant surge in stock prices following the release of groundbreaking asthma trial results. The new data from Jasper’s latest clinical trial indicates promising outcomes for their innovative asthma treatment, sparking investor interest and media attention. The trial’s success marks a critical milestone for the company, as it highlights their commitment to addressing unmet medical needs in respiratory care. This boost in stock value underscores market confidence in Jasper Therapeutics’ forward momentum and potential to reshape asthma treatment. With continued advancements in their pipeline, Jasper Therapeutics is poised to make substantial contributions to healthcare, attracting both investors and industry partners.
parameter.ioNew data shows New Hampshire Gains Thousands More Residents as Influx Continues
March 16, 2026
The latest U.S. Census data reveals a significant population increase in New Hampshire, with approximately 6,500 more people moving into the state than leaving in